



## Roles of the Wnt effector POP-1/TCF in the *C. elegans* endomesoderm specification gene network<sup>☆</sup>

Melissa Owrighi<sup>1</sup>, Gina Broitman-Maduro, Thomas Luu, Heather Roberson, Morris F. Maduro<sup>\*</sup>

Department of Biology, University of California, 2121A Genomics Building, Riverside, Riverside, CA 92521, USA

### ARTICLE INFO

#### Article history:

Received for publication 22 July 2009

Revised 23 September 2009

Accepted 25 September 2009

Available online 7 October 2009

doi:10.1016/j.ydbio.2009.09.042

#### Keywords:

*C. elegans*  
Endomesoderm  
Specification  
POP-1  
Gene network

### ABSTRACT

In *C. elegans* the 4-cell stage blastomere EMS is an endomesodermal precursor. Its anterior daughter, MS, makes primarily mesodermal cells, while its posterior daughter E generates the entire intestine. The gene regulatory network underlying specification of MS and E has been the subject of study for more than 15 years. A key component of the specification of the two cells is the involvement of the Wnt/ $\beta$ -catenin asymmetry pathway, which through its nuclear effector POP-1, specifies MS and E as different from each other. Loss of *pop-1* function results in the mis-specification of MS as an E-like cell, because POP-1 directly represses the *end-1* and *end-3* genes in MS, which would otherwise promote an endoderm fate. A long-standing question has been whether POP-1 plays a role in specifying MS fate beyond repression of endoderm fate. This question has been difficult to ask because the only chromosomal lesions that remove both *end-1* and *end-3* are large deletions removing hundreds of genes. Here, we report the construction of bona fide *end-1 end-3* double mutants. In embryos lacking activity of *end-1*, *end-3* and *pop-1* together, we find that MS fate is partially restored, while E expresses early markers of MS fate and adopts characteristics of both MS and C. Our results suggest that POP-1 is not critical for MS specification beyond repression of endoderm specification, and reveal that Wnt-modified POP-1 and END-1/3 further reinforce E specification by repressing MS fate in E. By comparison, a previous work suggested that in the related nematode *C. briggsae*, *Cb-POP-1* is not required to repress endoderm specification in MS, in direct contrast with *Ce-POP-1*, but is critical for repression of MS fate in E. The findings reported here shed new light on the flexibility of combinatorial control mechanisms in endomesoderm specification in *Caenorhabditis*.

© 2009 Elsevier Inc. All rights reserved.

### Introduction

Combinatorial control, achieved through spatiotemporally precise activation of genes in regulatory networks, is a central mechanism by which cells choose appropriate pathways of cell specification in metazoan development. Elucidation of such networks allows an appreciation for the complexity of the instructions encoded in the genome that bring about embryogenesis from the zygote. The endomesoderm specification network in the nematode *C. elegans* is a model for such networks in general. While an exhaustive compendium of protein–DNA interactions has yet to be made, many years of forward and reverse genetics, transcriptome analysis and protein–DNA studies have revealed a core network that includes motifs found in many other similar networks, such as feed-forward loops and autoregulation (Maduro, 2006). Evolutionary comparisons

of this network have begun to be performed in related nematodes, and important similarities and differences have been identified (Coroian et al., 2005; Lin et al., 2009).

In *C. elegans*, the 4-cell stage blastomere EMS is an endomesoderm precursor: its anterior daughter, MS, generates some 80 cells that are primarily mesodermal, which includes a portion of the body muscles, many posterior cells of the pharynx, and four embryonically-derived coelomocytes (Fig. 1A) (Sulston et al., 1983). Its posterior sister E is the sole endoderm progenitor and generates 20 intestinal cells. Specification of MS and E involves the participation of two pathways that work in parallel (Fig. 1B): the SKN-1 pathway assigns endomesodermal identity to the EMS daughters, while the Wnt/ $\beta$ -catenin asymmetry pathway directs the two cells to adopt different fates (Bowerman et al., 1992; Lin et al., 1995; Maduro and Rothman, 2002; Mizumoto and Sawa, 2007; Rocheleau et al., 1997; Rocheleau et al., 1999; Thorpe et al., 1997).


Endomesoderm specification begins with maternal SKN-1, a bZIP/homeodomain transcription factor that is present in the nuclei of EMS and its sister P<sub>2</sub> at the 4-cell stage (Bowerman et al., 1993). Loss of SKN-1 leads to mis-specification of MS all the time, and E most (~70–80%) of the time (Bowerman et al., 1992). In addition to the MS-derived posterior portion of the pharynx, mutants for *skn-1*

<sup>☆</sup> This article was accepted in 2009 to celebrate the 50th anniversary of Developmental Biology.

<sup>\*</sup> Corresponding author. Fax: +1 951 827 4286.

E-mail address: [mmaduro@ucr.edu](mailto:mmaduro@ucr.edu) (M.F. Maduro).

<sup>1</sup> Graduate Program in Cell, Molecular and Developmental Biology, UC Riverside, USA.



**Fig. 1.** The early *C. elegans* lineage and an abbreviated version of the endomesoderm gene regulatory network. (A) An abbreviated lineage shows the origin of the six founder cells and tissues made by each, with numbers of cells for gut, pharynx, muscle and coelomocytes in brackets (Sulston et al., 1983). Diagrams of an 8-cell stage embryo and larva show the lineal origins of the components of the digestive tract: Foregut/pharynx, midgut, and hindgut/rectum (h.g.). The assignment of ABa to 'anterior' pharynx and MS to 'posterior' pharynx is convenient but not strictly correct (Priess et al., 1987). On the larva, coelomocytes are indicated by 'CC'. (B) A flow diagram depicts a simplified version of the endomesoderm gene regulatory network, showing combinatorial control through the SKN-1 and Wnt/ $\beta$ -catenin pathways (Broitman-Maduro et al., 2009; Maduro, 2008).

also lack the anterior portion of the pharynx, which is specified by a GLP-1/Notch-dependent cell–cell interaction between MS and descendants of the AB founder cell (Mello et al., 1994; Priess et al., 1987). Within EMS, SKN-1 activates expression of a presumptive ligand for this interaction and the *med-1,2* divergent GATA factor gene pair (Lowry et al., 2009; Maduro et al., 2001). Loss of *med-1,2* together results in a penetrant mis-specification of MS, and low-penetrance mis-specification of E, owing to parallel inputs into E specification (Broitman-Maduro et al., 2009; Goszczynski and McGhee, 2005; Maduro et al., 2007; Maduro et al., 2001). Within the early MS lineage, the MEDs activate the T-box gene *tbx-35*, and TBX-35 (perhaps in combination with another factor) activates the NK-2 homeobox gene *ceh-51* (Broitman-Maduro et al., 2009). Loss of *tbx-35* and *ceh-51* together results in a penetrant mis-specification of MS that resembles the MS phenotype of *med-1,2* mutants (Broitman-Maduro et al., 2009). TBX-35 and CEH-51 are hypothesized to activate further pathways that lead to specification of pharynx, muscle and other tissues made by MS. Pharynx specification involves activation of a gene network with PHA-4/FoxA at the top (Gaudet and Mango, 2002), and which includes the pharynx muscle-specific regulator CEH-22/Nkx2.5 (Okkema and Fire, 1994). Muscle specification occurs via a three-way collaboration of HND-1/Hand, HLH-1/MyoD and UNC-120/Srf (Fukushige et al., 2006) and activation of a muscle gene network (Roy et al., 2002).

Within the early E lineage, the MEDs, SKN-1, the Wnt effector POP-1/TCF, and PAL-1/Caudal contribute to endoderm specification through activation of the GATA factor genes *end-1* and *end-3*. Expression of *end-3* occurs slightly earlier than *end-1* and there is evidence that END-3 also contributes to *end-1* activation (Baugh et al., 2003; Maduro et al., 2007). Downstream of *end-1,3*, the principal target is the GATA factor gene *elt-2* (Fukushige et al., 1998), which activates a network of targets for intestinal development (McGhee et al., 2009; McGhee et al., 2007; Pauli et al., 2006).

For both MS and E, loss of function of SKN-1, the MEDs, ENDS or TBX-35/CEH-51 causes adoption of a C-like fate by the mis-specified blastomeres. In contrast, mutations in the Wnt/ $\beta$ -catenin asymmetry pathway, which makes MS and E different, result in either an MS to E transformation (a 'Pop' phenotype) or the reverse, an E to MS transformation (a 'Mom' phenotype). Specification of E requires a cell–cell interaction between EMS and its sister P<sub>2</sub> (Goldstein, 1992). This interaction involves overlapping Wnt/MAPK/Src pathways and ultimately results in differential modification of the nuclear effector POP-1/TCF (Bei et al., 2002; Lin et al., 1998; Lin et al., 1995; Meneghini

et al., 1999; Rocheleau et al., 1997; Rocheleau et al., 1999; Shin et al., 1999; Thorpe et al., 1997). This modification results in the nuclear export of POP-1 in E (a phenomenon called 'POP-1 asymmetry'), lowering its concentrations relative to the divergent  $\beta$ -catenin SYS-1, and permitting it to function as an activator in E (Huang et al., 2007; Maduro et al., 2002; Phillips et al., 2007). Within MS, the high nuclear levels of POP-1 allow it to repress *end-1* and *end-3*, while in E, POP-1 contributes to activation of (at least) *end-1* (Maduro et al., 2005b; Maduro et al., 2002; Shetty et al., 2005). Mutations in the upstream Wnt/MAPK/Src components result in a Mom phenotype, while loss of *pop-1* is epistatic to Mom mutants and results in a Pop phenotype. POP-1 and the Wnt/ $\beta$ -catenin asymmetry pathway form a switch that is used multiple times in *C. elegans* development (Kaletta et al., 1997; Lin et al., 1998; Mizumoto and Sawa, 2007).

Outside of the EMS lineage, multiple parallel pathways block activity of SKN-1 or promote its degradation (Bei et al., 2002; Lin, 2003; Maduro et al., 2001; Mello et al., 1992; Page et al., 2007; Shirayama et al., 2006). For example, the CCCH zinc finger protein PIE-1 blocks activity of SKN-1 in P<sub>2</sub>: loss of *pie-1* function results in an ectopic mis-specification of the P<sub>2</sub> daughters as MS- and E-like (Mello et al., 1992). Similarly, a gain-of-function mutation in *oma-1*, which encodes a zinc finger protein similar to PIE-1, results in ectopic mis-specification of the C blastomere as an EMS-like cell, due to increased concentrations of SKN-1 in C (Lin, 2003).

The POP-1 switching system in *C. elegans* participates in the MS/E decision primarily by repressing endoderm specification in MS, although it makes a weaker contribution to endoderm specification in E (Lin et al., 1995; Shetty et al., 2005). In the related nematode, *C. briggsae*, analysis of the *Cb-pop-1* and *Cb-skn-1* RNAi phenotypes led to the conclusion that *Cb-POP-1* contributes to MS and E specification primarily as an essential activator of the *Cb-end* genes in E, with a parallel function in MS specification with *Cb-SKN-1* (Lin et al., 2009). This observation, along with other observations regarding expression of MS factors in *pop-1*-depleted embryos (Broitman-Maduro et al., 2006; Broitman-Maduro et al., 2009), prompted us to examine the role of *C. elegans* POP-1 in MS outside of repression of endoderm specification.

Here, we describe the construction of chromosomal *end-1 end-3* double mutants, and from a fully penetrant gut defect, conclude that these two genes are completely essential for endoderm specification in *C. elegans*. We test the requirement for POP-1 in MS specification outside of repression of the *ends*, and find that loss of *pop-1* function in *end-3* single mutants, and *end-1,3* double mutants, results in an apparent restoration of some aspects of MS specification to the MS

cell, and a transformation of the E lineage to one that makes both MS- and C-like tissues. Loss of *end-1,3*, or loss of *pop-1*, results in derepression of MS specification genes in the early E lineage, implying other functions for these regulators in E. These findings are integrated into an updated model for the *C. elegans* endomesoderm gene specification network, and are discussed in terms of a hierarchy of competing cell specification pathways and evolutionary flexibility in combinatorial control.

## Materials and methods

### Mutations and transgenic strains

Mutants: LG X: *med-1(ok804)*. I: *pop-1(zu189)*, *dpy-5(e61)*. II: *tbx-35(tm1789)*. III: *med-2(cx9744)*, *unc-119(ed3)*, *unc-119(ed4)*. IV: *him-8(e1498)*. V: *end-1(ok558)*, *end-3(ok1448)*, *end-3(zu247)*, *dpy-11(e224)*, *unc-76(e911)*, *him-5(e1490)*, *ceh-51(tm2123)*. Rearrangements: *hT1 [I;V]*. Mapped reporters: *wls84 [elt-2::GFP] X*, *gvl5402 [unc-120::GFP] I*, *cdls42 [cup-4::GFP] I*, *cdls41 [cup-4::GFP] II*, *ruls37 [myo-2::GFP] III*, *pxls6 [pha-4::GFP] IV*, *culs1 [ceh-22::GFP] V*. Unmapped: *qtls9 [nhr-25::YFP]*, *wls117 [med-1::GFP::POP-1]*. Extrachromosomal arrays: *teEx226 [tbx-35::GFP]*, *teEx420 [med-1::GFP::SYS-1]*. All *pop-1(zu189)* chromosomes also carried *dpy-5(e61)*, permitting identification of homozygous *zu189* mothers by their Dpy phenotype.

### Construction of *end-1 end-3* double mutant strains

We constructed a *dpy-11 end-1 unc-76* triple mutant using standard methods (Fay, 2006) and confirmed homozygosity of *ok558* by PCR. We obtained *dpy-11 end-1 unc-76/end-3(ok1448)* heterozygotes after crossing with *end-3(ok1448)* males, from which 120 Dpy non-Unc self progeny were singled. Two of these segregated ~25% dead eggs lacking endoderm. We injected one of these with *end-3(+)* (pMM214) and *unc-119::CFP* (pMM809) to generate a *dpy-11 end-1,3; Ex[CFP]* line. PCR was used to confirm the presence of *ok558* and *ok1448* and absence of wild-type chromosomal *end-1* and *end-3* sequences (primer sequences are available on request). A similar strategy was used to recover a *dpy-11 end-1 end-3(zu247)* strain from 93 Dpy non-Unc progeny of *dpy-11 end-1 unc-76/end-3(zu247)* heterozygotes. Strains were backcrossed to N2 to remove *dpy-11*, and derivative strains marked with *unc-119::YFP* (pMM531), *unc-119::mCherry* (pMM824) or *sur-5::dsRed* (pAS152) in the rescuing arrays were made by microinjection to replace the CFP-expressing array. Such strains are superficially wild-type and segregate arrested embryos and larvae that lack the transgene array. In total, three independent *end-1,3* double mutants were isolated at a frequency of 1.4% ( $n=213$ ), comparable to the predicted frequency of 1.5% obtained by subtracting the *end-1* and *end-3* interpolated genetic positions and dividing by the *dpy-11 unc-76* genetic distance in WormBase (WS200).

To introduce the *end-1(ok558) end-3(ok1448)* chromosome into a *pop-1(zu189)* strain, males from MS749 [*pop-1 dpy-5/hT1[I;V] I; ruls37 unc-119 III; him-5/him-5 hT1[I;V] V*] were crossed to *end-1,3; Ex[unc-119::CFP]* hermaphrodites. F<sub>1</sub> CFP(+) males were crossed to MS749 to generate strain MS1172 [*pop-1 dpy-5/hT1 I; ruls37 III; end-1,3/him-5 hT1 V*]. From 50 singled wild-type CFP(+) MS1172 hermaphrodites, we obtained three isolates of genotype *pop-1 dpy-5/hT1 I; end-1,3/end-1,3 hT1 V; ruls37 III; Ex[unc-119::CFP]* as confirmed by the absence of CFP(−) progeny that contained gut.

A *med-1,2; end-1,3* mutant strain was made as follows. *med-1; med-2* males rescued by an *unc-119::CFP* array carrying *med-1(+)* were crossed to a *dpy-11 end-1 end-3; pha-4::GFP* strain rescued by an array carrying *end-3(+)* and *unc-119::YFP*. Dpy F<sub>2</sub> hermaphrodites expressing YFP, CFP and GFP were singled to identify those showing complete transgene dependence on the *med (+)* and *end (+)* arrays, and which showed 100% transmission of *pha-4::GFP*. The two arrays

were replaced by a single array expressing *unc-119::mCherry* and which carried cosmids T24D3 (*med-1(+)*) and F58E10 (*end-1,3(+)*). A *cup-4::GFP* version was made using a similar strategy.

To make a *tbx-35; end-1 end-3 ceh-51* strain, we first constructed ++ *ceh-51/end-1 end-3+* hermaphrodites carrying an *unc-119::CFP* array rescuing *ceh-51* and an *unc-119::YFP* array rescuing *end-1,3*. YFP(+), CFP(+) animals were identified in which all viable progeny expressed CFP and which segregated gutless embryos (hence *end-1 end-3 ceh-51/+ ceh-51*). YFP(+), CFP(+) animals were picked in the next generation and examined for expression of both arrays by all viable animals. These animals were crossed to rescued *tbx-35; ceh-51* males to generate a quadruple mutant *tbx-35; end-1 end-3 ceh-51* strain rescued by an *unc-119::mCherry* array (*tbx-35(+), ceh-51(+)*) and an *unc-119::YFP* array (*end-3(+)*). The *cup-4::GFP* and *pha-4::GFP* markers were introduced and the quadruple mutant genotypes re-segregated.

### Microscopy, imaging and laser ablations

Embryos were imaged on agar pads using an Olympus BX-61 equipped with a Canon 350D camera. Images were processed using Adobe Photoshop 7. In images for birefringent granules and fluorescent reporter expression, images from multiple focal planes were digitally combined. Laser ablations were performed at the UC Riverside Microscopy and Imaging Core Facility as described (Lin et al. 2009).

## Results

### Chromosomal loss of *end-1* and *end-3* blocks endoderm specification

END-1 and END-3 are GATA factors that contain a single zinc finger and associated basic domain (Lowry and Atchley, 2000; Maduro et al., 2005a; Zhu et al., 1997). The *end-1* and *end-3* genes are located ~30 kbp apart on chromosome V, apparently the products of an ancestral gene duplication (Gillis et al., 2007). Deletions that remove both *end-1* and *end-3* and a large number of neighboring genes, defining the Endoderm Determining Region (EDR), result in a one-fold embryonic arrest and a complete absence of gut (Zhu et al., 1997). In contrast, single mutants of *end-1* and *end-3* have only minor effects on endoderm. The *ok558* lesion of *end-1*, which removes the DNA-binding domain, results in no apparent phenotype, while the *zu247* allele, a missense mutation causing a P202L change in the END-3 DNA-binding domain, and *ok1448*, which deletes the domain, both result in mild endoderm defects (5%–9% lacking endoderm; Table 1 and Maduro et al., 2005a; Maduro et al., 2005b). The single *end*

**Table 1**  
Endoderm specification in wild-type and mutant strains.

Genotype	% of embryos containing endoderm <sup>a</sup>
Wild-type (N2)	100% (>500)
<i>end-1(ok558)</i>	100% (322)
<i>end-3(ok1448)</i>	95% (155)
<i>end-3(zu247)</i>	91% (247)
<i>end-1(ok558) end-3(ok1448)</i>	0% (190)
<i>end-1(ok558) end-3(zu247)</i>	0% (377)
<i>end-1(ok558) end-3(ok1448); Ex[end-1,3(+)]</i>	99% (134)
<i>end-1(ok558) end-3(zu247); Ex[end-1,3(+)]</i>	96% (83)
<i>end-1(ok558) end-3(ok1448); pie-1(RNAi)</i>	0% (49)
<i>end-1(ok558) end-3(zu247); pie-1(RNAi)</i>	0% (72)
<i>end-3(zu247); pop-1(RNAi)</i>	3% (175)
<i>end-3(ok1448); pop-1(zu189)<sup>b</sup></i>	9% (274)
<i>end-3(ok1448); pop-1(RNAi)</i>	1% (262)
<i>end-1(ok558) end-3(zu247); pop-1(RNAi)</i>	0% (51)
<i>end-1(ok558) end-3(ok1448); pop-1(RNAi)</i>	0% (127)
<i>end-1(ok558) end-3(ok1448); pop-1(zu189)<sup>b</sup></i>	0% (34)

<sup>a</sup> Some data were previously reported in Maduro et al. 2005b.


<sup>b</sup> Embryos were also homozygous for *dpy-5(e61)*.

mutants can enhance the penetrance of other mutants that themselves have only a partial endoderm specification defect (Maduro et al., 2005a; Maduro et al., 2005b). RNAi of *end-3* in an *end-1* mutant blocked endoderm specification in 89–93% of progeny embryos (Maduro et al., 2005a), but it was not resolved whether the incomplete penetrance reflected the efficiency of RNAi targeted to *end-3* or if there are other genes in the EDR that can contribute to endoderm specification. Indeed, a nuclear hormone receptor gene located in the EDR, R10D12.2/*dpr-1* (previously named *end-2*) could apparently rescue endoderm specification in a small proportion of transgenic embryos homozygous for a deficiency that removes *end-1* and *end-3* (Zhu et al., 1997).

To directly assess the requirement for *end-1* and *end-3* in endoderm specification, we constructed double mutants of *end-1* (*ok558*) with *end-3(ok1448)* and *end-3(zu247)* (see Materials and methods). As the same *end-1* allele was used for all analyses presented here, the *end-1(ok558) end-3(ok1448)* genotype will be referred to as *end-1,3(ok1448)* and the *end-1(ok558) end-3(zu247)* genotype as *end-1,3(zu247)*. Both *end-1,3(ok1448)* and *end-1,3(zu247)* double mutants failed to make endoderm 100% of the time ( $n=377$  and  $n=190$ ) as scored by morphology with DIC microscopy and using polarized light to detect birefringent gut granules (Figs. 2A–D) (Laufer et al., 1980). Hence, although the *zu247* allele is only a missense mutation, all endoderm specification in *end-3(zu247)* is dependent on *end-1*. Ectopic endoderm made in *pie-1(RNAi)* embryos also showed a requirement for *end-1,3* in the two strains (Table 1) (Mello et al., 1992). The majority of *end-1,3* embryos (83%,  $n=124$  for *end-1,3(ok1448)*) underwent a developmental arrest after completing elongation, with many of these eventually hatching as arrested L1s; the remainder arrested as embryos at varying stages of elongation. The gut, elongation and viability defects were restored to 96–99% of *end-1,3* double mutants by an array carrying *end-1(+)* and *end-3(+)* or *end-3(+)* alone (Table 1, Fig. 2 and data not shown).

Two additional phenotypes were noted among *end-1,3* mutant embryos. First, ectopic gut granule-like material was observed in the excretory cell in 11% ( $n=90$ ) of *end-1,3(zu247)* and 13% ( $n=106$ ) of *end-1,3(ok1448)* embryos (Fig. 2I). Second, while wild-type L1s were measured to be  $242 \pm 4.4 \mu\text{m}$  ( $n=12$ ) long, hatched *end-1(ok558) end-3(ok1448)* double mutants were only about 75% as long, with an average length of  $175 \pm 7 \mu\text{m}$  ( $n=19$ ,  $p < 10^{-8}$ ) (Fig. 2E). Such hatched *end-1,3* embryos frequently contained apparent hypodermal abnormalities (not shown). Excretory-cell granules and a contraction of embryo length were also reported for mutants in the *glo* genes, which have defects in gut granule biogenesis but nonetheless make an intestine (Hermann et al., 2005). At least one of these, *glo-1*, is expressed in the embryonic E lineage and the intestine through adulthood, and is proposed to be a target of END-1,3 (Hermann et al., 2005). By in situ hybridization, we detected transcripts for *glo-1* in the E lineage in 86% ( $n=49$ ) of wild-type embryos at gastrulation stage or later. In contrast, expression was detected in only 33% ( $n=42$ ) of embryos from an *end-1,3(ok1448)* strain rescued by an array with a transmission frequency of ~40%, consistent with the absence of *glo-1* expression in all *end-1,3* mutant embryos (data not shown). These results suggest that later embryonic phenotypes of *end-1,3* double mutants result from the absence of functions that are normally provided to the embryo by the gut, such as osmoregulation or lysosomal trafficking (Hermann et al., 2005).

In prior studies that examined the fate of E descendants in EDR deficiency embryos or following RNAi of *end-1* and *end-3*, E was observed to adopt a C-like fate, generating epidermis and body muscle cells instead of gut (Maduro et al., 2005a; Zhu et al., 1997). A small number of *end-3(zu247)* mutant embryos appeared to show evidence of partial transformation to an MS-like fate, suggesting that at least part of the E lineage can produce ectopic MS-like cells when endoderm specification is compromised (Maduro et al., 2005a). The chromosomal double *end-1,3* mutant embryos were examined for



**Fig. 2.** Chromosomal *end-1,3* double mutants lack endoderm. (A) DIC appearance of *end-1(ok558) end-3(ok1448)* embryos. The embryo on the left is rescued by an extrachromosomal transgene array carrying *end-1(+)* and *end-3(+)* (referred to as an *end-1,3(+)* array). On the middle embryo, internal cavities are indicated by arrowheads. (B) Polarized light micrograph showing appearance of birefringent gut granules in the rescued embryo (left, outlined in red) but not in the mutant embryos (outlined in yellow). (C) *end-1(ok558) end-3(zu247)* embryos. The embryo on the left carries an *end-1,3(+)* array. (D) Gut granules are present only in the rescued embryo (red outline). (E) Newly-hatched wild-type L1 (left) and arrested *end-1(ok558) end-3(ok1448)* double mutant. The gut in the wild-type has been shaded blue, and the pharynx and hindgut (rectum) have been shaded in red. The wild-type is approximately 240  $\mu\text{m}$  long. (F) Expression of *elt-2::GFP* (Fukushige et al., 1998) in a wild-type elongated embryo. DIC and fluorescence images have been digitally combined in this panel and panels G, H, J and K. (G, H) Absence of *elt-2* expression in *end-1(ok558) end-3(ok1448)* and *end-1(ok558) end-3(zu247)* embryos. (I) Accumulation of gut granule-like material in part of the excretory cell (arrowheads) of an *end-1(ok558) end-3(zu247)* arrested embryo. (J) Expression of *pha-4::GFP* (Horner et al., 1998; Kalb et al., 1998) in a developing *end-1,3* embryo carrying an *end-1,3(+)* array. The pharynx and hindgut (h.g.) components of *pha-4* expression are indicated; the remaining expressing cells are from the developing intestine. (K) Absence of the intestinal component of *pha-4* expression in an *end-1(ok558) end-3(ok1448)* embryo at a similar stage as panel J. (L) *end-1(ok558) end-3(ok1448)* embryos arrested with a one-fold appearance following heat shock overexpression of *elt-2*. Two embryos that carry an *end-1,3(+)* array are indicated. (M) Accumulation of large amounts of gut granules in rescued (red outline) and non-rescued (yellow outline) embryos. A C. elegans embryo is approximately 50  $\mu\text{m}$  long. In panels J and K, anterior is to the left and dorsal is up.

evidence of the tissue types made by E descendants. First, the formation of internal cavities has previously been associated with internalization of ectopic C-like cells in *skn-1*, *med-1,2* or *tbx-35* mutants, resulting in ectopic epidermis in the descendants (Bowerman et al., 1992; Broitman-Maduro et al., 2006). We observed such cavities in 13% ( $n = 176$ ) of *end-1(ok558) end-3(zu247)* and 15% ( $n = 124$ ) of *end-1(ok558) end-3(ok1448)* embryos (Fig. 2A and data not shown). By comparison, cavities were observed in approximately 30% of *med-1,2* and *tbx-35* mutants (Broitman-Maduro et al., 2006; Maduro et al., 2001).

To more precisely evaluate the fate of E descendants in *end-1,3* embryos, a laser microbeam was used to isolate early blastomeres in *end-1,3(ok1448)* embryos carrying various tissue-specific reporters. Expression of *nhr-25::YFP*, a reporter that is normally expressed in epidermis (Baugh et al., 2005), did not occur in the embryonic intestine of intact embryos ( $n = 80$ ), while descendants of isolated C blastomeres showed expression as expected (5/5 partial embryos). However, 10/10 isolated E blastomeres from *end-1,3(ok1448)* embryos displayed *nhr-25::YFP* (Table 3). Production of body muscle cells from isolated E blastomeres was observed in *end-1,3(ok1448)* mutant embryos ( $n = 3$ ) as assessed by expression of *unc-120::GFP* (Table 3) (Fukushige et al., 2006). Moreover, in intact *end-1,3(ok1448)* and *end-1,3(zu247)* embryos, neither ectopic pharynx (scored by *pha-4::GFP*) nor ectopic coelomocytes (*cup-4::GFP*) were apparent (Table 2) (Horner et al., 1998; Kalb et al., 1998; Patton et al., 2005). These results confirm that chromosomal loss of *end-1* and *end-3* results causes E to adopt a C-like fate, making body muscles and epidermal cells. Furthermore, we could find no evidence that such embryos produce ectopic pharynx or coelomocyte cells as would be consistent with ectopic MS specification.

The apparent target of *end-1* and *end-3* is the GATA factor gene *elt-2* (Fukushige et al., 1998; Maduro et al., 2005a; Maduro and Rothman, 2002). *ELT-2* is not essential for embryonic gut specification, but is required for maintenance of the gut fate (Fukushige et al., 1998). A chromosomally integrated *elt-2::GFP* reporter was introduced into the *end-1,3* double mutants. Expression of *elt-2* was absent in 100% ( $n = 112$ ) of *end-1,3(ok1448)* and 100% ( $n = 142$ ) of *end-1,3(zu247)* embryos (Figs. 2F–H). Similarly, expression of a reporter for the gut esterase gene *ges-1*, a direct target of *ELT-2* (Egan et al., 1995), and the intestine expression of *pha-4* (Horner et al., 1998), were both absent in *end-1,3(ok1448)* double mutants ( $n = 238$  and  $n = 30$ , respectively;

Figs. 2J, K). Hence, *end-1* and *end-3* together are necessary for activation of *elt-2* and its downstream targets.

To test if overexpression of *ELT-2* in an *end-1 end-3* double mutant background was sufficient to restore endoderm, we introduced a heat shock (*hs*) *elt-2* integrated transgene (Fukushige et al., 1998) into the *end-1,3(ok1448)* background rescued by a transgenic *end-1,3(+)* extrachromosomal array that can be scored for its presence by *sur-5::dsRed* expression (Yochem et al., 1998). Among heat shocked embryos that contained excess gut, 36% (16/44) carried the *end-1,3(+)* rescuing array, while the remainder (64%, 28/44) did not, confirming that overexpression of *ELT-2* is sufficient to specify intestinal fate in the absence of *end-1* and *end-3* (Figs. 2L, M).

Taken together, these results confirm that *end-1* and *end-3* together are essential for endoderm specification, that E adopts a C-like fate in *end-1,3* double mutants, and that a key contribution of *END-1,3* to intestine fate is the activation of *elt-2*. Furthermore, the ability of *end-1,3* mutants to elongate and hatch demonstrates the capacity of the embryo to undergo morphogenesis in the complete absence of the endoderm.

#### MS-derived tissues are made in *pop-1; end-3* and *pop-1; end-1,3* embryos

The nuclear Wnt effector TCF/POP-1 plays a central role in specification of MS. Loss of maternal *pop-1* function through the maternal-specific allele *zu189* or by RNAi results in a penetrant mis-specification of MS as an E-like precursor (Lin et al., 1998; Lin et al., 1995). Consistent with negative regulation of the *end* genes by POP-1 in MS, *end-1* and *end-3* are expressed ectopically in both MS and E in *pop-1* mutant embryos (Maduro et al., 2005a; Maduro et al., 2007; Shetty et al., 2005). This repression is direct, as GFP::POP-1 interacts in vivo with extrachromosomal arrays containing either promoter (Maduro et al., 2002), and a POP-1 binding site is required for repression of an *end-1* transgene reporter in the early MS lineage (Shetty et al., 2005). What has not been clear from prior studies with *pop-1* and MS fate is whether there is a requirement for POP-1 in MS in addition to repression of endoderm fate. Indeed, the MS specification genes *tbx-35* and *ceh-51* are still expressed in MS in *pop-1* mutants (Broitman-Maduro et al., 2006; Broitman-Maduro et al., 2009), suggesting that the normal pathways for MS specification might still be active.

**Table 2**  
Coelomocytes and pharynx cells made in wild-type, mutant and RNAi backgrounds.

Genotype	Coelomocytes <i>cup-4::GFP</i> <sup>a</sup>	Pharynx cells <i>pha-4::GFP</i> <sup>a,b</sup>
Wild-type (N2)	3.7 ± 0.2 (105)	50.0 ± 0.9 (21)
<i>pop-1(RNAi)</i>	0.0 ± 0.0 (50)	21.3 ± 0.8 (18)
<i>gfp-1(RNAi)</i>	nd	23.1 ± 0.6 (15)
<i>end-1(ok558) end-3(ok1448)</i>	4.5 ± 0.1 (65)	49.1 ± 1.0 (10)
<i>end-1(ok558) end-3(zu247)</i>	4.6 ± 0.1 (77)	51.1 ± 1.3 (15)
<i>end-3(ok1448); pop-1(RNAi)</i>	6.1 ± 0.2 (77)	28.5 ± 7.0 (22)
<i>end-1(ok558) end-3(zu247); pop-1(RNAi)</i>	9.3 ± 0.2 (80)	43.5 ± 1.3 (23)
<i>end-1(ok558) end-3(ok1448); pop-1(RNAi)</i>	10.7 ± 0.3 (77)	44.8 ± 2.2 (17)
<i>end-3(ok1448); gfp-1(or178)</i>	nd	21.2 ± 0.8 (18)
<i>end-3(ok1448); gfp-1(or178); pop-1(RNAi)</i>	nd	9.5 ± 0.8 (75)
<i>end-1(ok558) end-3(ok1448); gfp-1(or178)</i>	nd	25.2 ± 1.0 (17)
<i>end-1(ok558) end-3(ok1448); gfp-1(or178); pop-1(RNAi)</i>	nd	16.8 ± 1.1 (93)
<i>end-1(ok558) end-3(ok1448); gfp-1(or178); pop-1(RNAi); Ex[end-1,3(+)]</i>	nd	1.4 ± 0.3 (40)
<i>med-1(ok804); med-2(cx9744)</i>	0.1 ± 0.0 (34)	31.3 ± 0.6 (26)
<i>tbx-35(tm1789); ceh-51(tm2123)</i>	0.2 ± 0.0 (124)	30.2 ± 0.5 (44)
<i>med-1(ok804); med-2(cx9744); end-1(ok558) end-3(ok1448)</i> <sup>c</sup>	0.0 ± 0.0 (52)	29.9 ± 1.1 (12)
<i>med-1(ok804); med-2(cx9744); end-1(ok558) end-3(ok1448); pop-1(RNAi)</i> <sup>c</sup>	1.0 ± 0.2 (57)	22.4 ± 0.9 (24)
<i>tbx-35(tm1789); end-1(ok558) end-3(ok1448) ceh-51(tm2123)</i>	0.1 ± 0.0 (122)	30.3 ± 1.0 (21)
<i>tbx-35(tm1789); end-1(ok558) end-3(ok1448) ceh-51(tm2123); pop-1(RNAi)</i>	0.1 ± 0.1 (35)	22.1 ± 1.4 (19)

<sup>a</sup> Some data are from Broitman-Maduro et al. 2009.

<sup>b</sup> Expression of *pha-4* in gut and/or rectum cells (if present) was not included.

<sup>c</sup> Embryos were also homozygous for *dpy-11(e224)*.

**Table 3**  
Production of tissues in laser-operated embryos.

Genotype	Blastomeres ablated or isolated	Partial embryos making tissues (# of cells)			
		Coelomocytes ( <i>cup-4::GFP</i> )	Pharynx muscle ( <i>myo-2::GFP</i> ) <sup>a</sup>	Body muscle ( <i>unc-120::GFP</i> )	Epidermis ( <i>nhr-25::YFP</i> ) <sup>a</sup>
Wild-type	MS abl.	0/3 (0.0 ± 0.0)	–	–	–
	MS iso.	3/3 (4.0 ± 0.0)	–	–	0/1
	E iso.	0/6 (0.0 ± 0.0)	–	0/4 (0.0 ± 0.0)	0/6
	C iso.	–	–	–	5/5
<i>skn-1(RNAi)</i>	MS iso.	–	–	–	3/3
	MS abl.	0/5 (0.0 ± 0.0)	–	–	–
<i>end-3(ok1448)</i>	E abl.	2/2 (4.0 ± 0.0)	–	–	–
	ABa + MS abl.	–	3/3 (weak)	–	–
	ABa + E abl.	–	2/2	–	–
<i>end-3(ok1448); pop-1(zu189)<sup>b</sup></i>	ABa + MS + E abl.	–	0/3	–	–
	MS abl.	4/4 (3.0 ± 0.6)	–	–	–
	E abl.	5/5 (3.0 ± 0.5)	–	–	–
<i>end-3(ok1448); pop-1(RNAi)</i>	MS + E abl.	1/4 (0.3 ± 0.2)	–	–	–
	MS abl.	1/5 (0.2 ± 0.2)	–	–	–
	E abl.	5/5 (3.6 ± 0.2)	–	–	–
<i>end-1(ok558) end-3(ok1448)</i>	MS + E abl.	0/3 (0.0 ± 0.0)	–	–	–
	MS iso.	5/5 (4.0 ± 0.0) <sup>c</sup>	–	3/3 (18.7 ± 2.0)	0/5 <sup>3</sup>
	E iso.	0/4 (0.0 ± 0.0) <sup>c</sup>	–	3/3 (15.3 ± 0.7)	10/10 <sup>3</sup>
	MS abl.	–	1/1	–	–
	ABa abl.	–	0/3	–	–
<i>pop-1(zu189)<sup>b</sup></i>	MS iso.	–	–	–	0/3
	E iso.	–	–	–	0/4
<i>end-1(ok558) end-3(ok1448); pop-1(zu189)<sup>b</sup></i>	ABa + MS abl.	–	5/5	–	–
	ABa + E abl.	–	4/4	–	–
	ABa + MS + E	–	0/3	–	–
<i>end-1(ok558) end-3(ok1448); pop-1(RNAi)</i>	MS abl.	3/3 (6.7 ± 0.5)	–	–	–
	E abl.	3/3 (4.7 ± 0.7)	–	–	–
	MS + E abl.	0/4 (0.0 ± 0.0)	–	–	–
	MS iso.	4/4 (5.0 ± 0.4)	–	–	0/8
	E iso.	6/6 (5.5 ± 0.3)	–	6/6 (10.2 ± 1.2)	9/11
	ABx + MS abl.	–	5/8	–	–
ABx + E abl.	–	4/6	–	–	

Abbreviations: abl, ablated; iso, isolated (all other blastomeres ablated); ABx, both daughters of AB were ablated.

<sup>a</sup> Numbers of cells were not counted because individual cells could not be distinguished.

<sup>b</sup> Embryos from homozygous *pop-1(zu189) dpy-5(e61)* mothers (with other mutations as indicated).


<sup>c</sup> Numbers from experiments on a strain carrying both *nhr-25::YFP* and *cup-4::GFP* were included.

A direct assessment of the involvement of POP-1 in MS specification could be made by evaluating the phenotype of *pop-1* mutant embryos in which endoderm specification is blocked by reduction or elimination of *end* activity. Interpretation of these results may be complicated by the fact that POP-1 and the Wnt/ $\beta$ -catenin asymmetry pathway function in many asymmetric cell divisions, including those that follow the MS-E division within the endomesoderm (Huang et al., 2007; Kaletta et al., 1997; Lin et al., 1998; Maduro et al., 2002; Mizumoto and Sawa, 2007; Schroeder and McGhee, 1998). In the embryo, *pop-1* function in MS and E is contributed maternally, as revealed by the maternal-effect *zu189* allele of *pop-1* (Lin et al., 1995). In contrast, *pop-1(RNAi)* abolishes both the zygotic and maternal contributions of *pop-1*, resulting in a more severe phenotype in *pop-1(RNAi)* embryos compared to *pop-1(zu189)* (Lin et al., 1998). Hence, to make the best assessment of MS specification, we have evaluated both *pop-1(zu189)* and *pop-1(RNAi)* backgrounds, and used multiple criteria to evaluate production of MS-derived tissues.

A further complication could arise if mutation of *end-1,3* affected ratios of POP-1::SYS-1, the primary determinant of POP-1 function as a repressor or activator (Huang et al., 2007; Phillips et al., 2007). However, this seems highly unlikely, as zygotic expression of the *end* genes is determined by, and occurs downstream of, the activity of maternal POP-1 and SYS-1 proteins (Huang et al., 2007; Maduro et al., 2007; Shetty et al., 2005). Nonetheless, we examined *med-1*-driven GFP::SYS-1 and GFP::POP-1 reporter strains in an *end-1,3(ok1448)* mutant background and saw no apparent effect on SYS-1 or POP-1 protein asymmetries (data not shown) (Huang et al., 2007; Maduro et al., 2002).

Previous results suggested that a potent knockdown of endoderm specification occurs in *end-3; pop-1* mutant embryos. END-3 appears to contribute to *end-1* activation (Maduro et al., 2007), and POP-1 makes a positive contribution to *end* expression in E (Phillips et al., 2007; Shetty et al., 2005). As a result, although there is also input into endoderm specification by SKN-1, MED-1,2 and PAL-1, loss of *pop-1* and *end-3* compromises *end-1* activation enough that endoderm fails to be specified in 91–99% of embryos (Table 1) (Maduro et al., 2007; Maduro et al., 2005b; Maduro et al., 2001). Because *end-3* homozygotes are viable, we performed our first studies with *end-3; pop-1* embryos, then subsequently with *end-1,3; pop-1* embryos when the double *end-1,3* mutants became available. The results of both sets of experiments, collectively referred to as *end; pop-1*, are described below and summarized in Tables 2 and 3.

We examined *end-3(ok1448); pop-1(RNAi)* and *end-1(ok558) end-3(ok1448); pop-1(RNAi)* embryos for production of MS-derived tissues (Table 2). Using *pha-4::GFP* to score pharynx cells (Horner et al., 1998; Kalb et al., 1998), control *pop-1(RNAi)* embryos displayed an average of  $21.3 \pm 0.8$  ( $n = 18$ ) pharynx cells (compared with wild-type,  $50.0 \pm 0.9$ ,  $n = 21$ ), consistent with the loss of MS-derived pharynx resulting from an MS-to-E transformation (Figs. 2J and 3C). In contrast, *end-3(ok1448); pop-1(RNAi)* embryos contained  $28.5 \pm 7.0$  ( $n = 22$ ) pharynx cells ( $p < 0.0002$  compared with *pop-1(RNAi)* alone), while *end-1,3(ok1448); pop-1(RNAi)* and *end-1,3(zu247); pop-1(RNAi)* embryos had  $44.8 \pm 2.2$  ( $n = 17$ ) and  $43.5 \pm 1.3$  ( $n = 23$ ) pharynx cells each ( $p < 10^{-14}$  compared with *pop-1(RNAi)* alone) (Fig. 3G and data not shown). From the absence of gut, and the presence of significantly more pharynx cells in *end-1,3; pop-1* embryos over *pop-1* alone, the most straightforward



**Fig. 3.** Embryos lacking *end* and *pop-1* function make MS-type pharynx. (A) Polarized light image of a field of *end-1(ok558) end-3(ok1448); glp-1(or178ts)* embryos raised at the non-permissive temperature for *or178* and treated with *pop-1(RNAi)*. The two embryos on the left (outlined in red) carry an *end-1,3(+)* transgene and are the only embryos making gut. (B) Fluorescence image of the same embryos in panel A showing *pha-4::GFP* expression (Horner et al., 1998; Kalb et al., 1998). Expression in the two rescued embryos (red outline) is from gut cells, while in the remaining embryos expression is from GLP-1-independent pharynx cells (an average of  $16.8 \pm 1.1$  cells,  $n=93$ ). Hindgut cells (as seen in panels K–N) are not made in strong *glp-1* mutants due to a transformation of ABp to ABa (Mello et al., 1994). (C) GFP overlay of *pha-4::GFP* expression in a *pop-1(RNAi)* embryo. The bright signals in large nuclei are gut nuclei (confirmed by polarized light birefringence), while the remaining expression is from hindgut cells (h.g.) and ABa-derived pharynx (an average of  $21.3 \pm 0.8$  cells,  $n=18$ ). (D) Elongated wild-type embryo with grinder (gr) indicated. (E) Arrested *pop-1(zu189) dpy-5(e61)* embryo from a *pop-1 dpy-5* mother. (F) Arrested *end-1(ok558) end-3(ok1448); pop-1(zu189) dpy-5(e61)* embryo from an *end-1,3; pop-1 dpy-5* mother rescued by an *end-1,3(+)* transgene. The grinder (gr) within a posterior pharynx-like structure is indicated. (G) Expression of *pha-4::GFP* in an *end-1(ok558) end-3(ok1448); pop-1(RNAi)* embryo in hindgut (h.g.) and pharynx (average of  $44.8 \pm 2.2$  pharynx cells,  $n=17$ ). (H–J) *myo-2::GFP* expression (Okkema et al., 1993) showing presence of ABA- and MS-derived portions of pharynx in wild-type (H) and *end-1,3; pop-1* (J) embryos, but lacking MS-derived pharynx in a *pop-1* mutant (I). (K–N) *pha-4::GFP* expression in chromosomal mutant backgrounds that block MS specification, with and without *pop-1(RNAi)*. (K, L) *med-1(ok804); med-2(cx9744); dpy-11(e224) end-1(ok558) end-3(ok1448)* background. (M, N) *tbx-35(tm1789); end-1(ok558) end-3(ok1448) ceh-51(tm2123)* background. In these mutant backgrounds, the number of *pha-4::GFP*-expressing cells is actually reduced from ~30 to ~22 when *pop-1(RNAi)* is added, owing to an apparent requirement for *pop-1* in ABa-derived pharynx (Table 2). An additional requirement for *pop-1* in morphogenesis (Lin et al., 1998) results in dispersal of *pha-4::GFP*-expressing cells in panels L and N. Embryos in most panels have been oriented with anterior to the left and dorsal up.

interpretation is that MS and/or E produced pharynx in *end; pop-1* embryos.

As MS-derived pharynx is produced independently of maternal GLP-1 (Priess et al., 1987), we examined whether *glp-1* was required for production of extra pharynx cells in *end; pop-1* embryos. First, *end-1,3(ok1448); glp-1(or178); pop-1(RNAi); Ex[end-1,3(+)]* embryos, rescued for endoderm specification by a transgene array, made almost no pharynx cells ( $1.4 \pm 0.3$  cells,  $n=40$ ) (Figs. 3A, B). This control result is consistent with the loss of both AB- and MS-derived pharynx in *glp-1; pop-1* mutant embryos (Lin et al., 1995). In contrast, non-rescued *end-1,3(ok1448); glp-1(or178); pop-1(RNAi)* embryos made  $16.8 \pm 1.1$  ( $n=93$ ) pharynx cells ( $p < 10^{-24}$ ) while *end-3(ok1448); glp-1(or178); pop-1(RNAi)* embryos made  $9.5 \pm 0.8$  ( $n=75$ ) cells ( $p < 10^{-13}$ ) (Figs. 3A, B). The complement of GLP-1-independent pharynx was  $21.3 \pm 0.8$  ( $n=18$ ) in *glp-1(RNAi)* embryos,  $21.2 \pm 0.8$  ( $n=18$ ) in *end-3(ok1448); glp-1(or178)* embryos, and  $25.2 \pm 1.0$  ( $n=17$ ) in *end-1,3(ok1448); glp-1(or178)* embryos

(Table 2). Hence, ~45% and ~67% of the number of GLP-1-independent pharynx cells are restored in *end-3(ok1448); pop-1(RNAi)* and *end-1,3(ok1448); pop-1(RNAi)* embryos, respectively.

To look for evidence that these pharynx cells were capable of undergoing organogenesis, we looked for a posterior pharynx in *end-1,3(ok1448); pop-1(zu189)* embryos that also carried a *myo-2::GFP* pharynx muscle reporter (Okkema et al., 1993). At least a partial grinder was visible in 23% ( $n=74$ ) of *end-1,3(ok1448); pop-1(zu189)* embryos, but this was never seen in sibling embryos that were rescued for *end-1,3* by a transgene array ( $n=43$ ) (Figs. 3D–F, H–J). This suggests that the additional pharynx cells made in *end-1,3; pop-1* embryos can sometimes undergo organogenesis to generate part of the posterior pharynx.

To examine the origin of the additional pharynx cells made in *end; pop-1(RNAi)* embryos, we performed laser ablations on embryos using *end-3(ok1448); pop-1(zu189)* and *end-1(ok558) end-3(ok1448); pop-1(zu189)* strains carrying a cytoplasmic *myo-2::GFP* reporter, which

marks pharynx muscle (Okkema et al., 1993). While ablation of ABa, MS and E together led to production of no pharynx muscle ( $n = 3$  for each genotype), ablation of only ABa + MS or ABa + E resulted in production of pharynx muscle in partial embryos of each genotype, although *myo-2* expression in ABa + MS ablated *end-3(ok1448)*; *pop-1(zu189)* embryos was somewhat weaker (Table 3). In a separate experiment, ablation of the AB daughters plus either MS or E in *end-1,3(ok1448)*; *pop-1(RNAi)* embryos resulted in *myo-2* expression in 5/8 and 4/6 partial embryos, respectively. These results suggest that both MS and E can produce MS-like tissues in *end-3*; *pop-1* and *end-1,3*; *pop-1* embryos.

Next, we tested for embryonic production of coelomocytes, which comprise four cells derived exclusively from MS (Sulston et al., 1983). As scored by a *cup-4::GFP* marker (Patton et al., 2005), *pop-1(RNAi)* embryos made no coelomocytes ( $n = 50$ ) compared with wild-types, which showed an average of  $3.7 \pm 0.2$  ( $n = 105$ ), and *end-1,3* mutants, which showed an average of  $\sim 4.5$  cells (Table 2, Figs. 4A–C). In contrast, *end-3(ok1448)*; *pop-1(RNAi)* embryos made an average of  $6.1 \pm 0.2$  ( $n = 77$ ) coelomocytes, *end-1,3(ok1448)*; *pop-1(RNAi)* embryos made an average of  $9.3 \pm 0.2$  ( $n = 80$ ), and *end-1,3(zu247)*; *pop-1(RNAi)* embryos made an average of  $10.7 \pm 0.3$  ( $n = 77$ ) (Figs. 4E, F and data not shown). Using a laser microbeam, we ablated MS, E, or both in *end-3(ok1448)* and *end-1,3(ok1448)* backgrounds with or without *pop-1(RNAi)*. The *end-3* and *end-1,3* backgrounds showed production of coelomocytes only from MS, while *end-3*; *pop-1* and *end-1,3*; *pop-1* showed production of coelomocytes from both MS and E (results summarized in Table 3). Taken together, these results suggest that coelomocytes and GLP-1-independent pharynx are made by both MS and E in *end*; *pop-1* embryos. This suggests that POP-1 is not essential for production of mesoderm tissue from MS, and furthermore, that POP-1 and/or END-1,3 may repress MS fate in the E cell. The failure to obtain a high number of completely restored MS-derived pharynxes implies additional requirements for POP-1 function in MS lineage development; this is consistent with known involvement of the Wnt/ $\beta$ -catenin asymmetry pathway in pharynx lineages in MS (Kaletta et al., 1997).


#### Restored MS-like fates in *end-1,3*; *pop-1* mutants require normal pathways for MS specification

The simplest explanation for the origin of MS-derived pharynx and coelomocytes in *end*; *pop-1* mutants is that these arise through activation of the same genes that specify MS in wild-type embryos. However, it is possible that mesoderm specification is activated later by some default mechanism in response to the absence of POP-1 and END-1,3. We have shown that *med-1,2* together, and *tbx-35*; *ceh-51*


together are essential for production of coelomocytes and GLP-1-independent pharynx (Figs. 3K, M and 4D) (Broitman-Maduro et al., 2009). To confirm that coelomocytes and pharynx cells made in *end*; *pop-1* mutant embryos are the result of normal MS specification, we constructed quadruple *med-1(ok804)*; *med-2(cx9744)*; *end-1(ok558)* *end-3(ok1448)* and *tbx-35(tm1789)*; *end-1(ok558)* *end-3(ok1448)* *ceh-51(tm2123)* mutant strains carrying *pha-4::GFP* or *cup-4::GFP* (see Materials and methods). As summarized in Table 2, both quadruple-mutant backgrounds resulted in loss of MS-derived coelomocytes (none, for *med-1,2*; *end-1,3* ( $n = 52$ ), and  $0.1 \pm 0.0$  ( $n = 122$ ) for *tbx-35*; *end-1,3* *ceh-51*), similar to *med-1,2* or *tbx-35*; *ceh-51* alone. However, even though *end-1,3*; *pop-1* embryos made an average of  $10.7 \pm 0.3$  ( $n = 77$ ) coelomocytes as reported above, addition of *pop-1(RNAi)* resulted in very few coelomocytes ( $1.0 \pm 0.2$  in the case of *med-1,2*; *end-1,3*; *pop-1(RNAi)* or nearly none ( $0.1 \pm 0.1$ ,  $n = 35$ ) in the case of *tbx-35*; *end-1,3* *ceh-51* (Figs. 4G, H). A similar pattern was observed for expression of *pha-4::GFP*: While *med-1,2*; *end-1,3* and *tbx-35*; *end-1,3* *ceh-51* quadruple mutants made  $29.9 \pm 1.1$  ( $n = 12$ ) and  $30.3 \pm 1.0$  ( $n = 21$ ) pharynx cells each, addition of *pop-1(RNAi)* did not result in an increase in pharynx cells as was seen with *end-1,3*; *pop-1* (Figs. 3C, L, N). Indeed, the quadruple mutant+ *pop-1(RNAi)* backgrounds produced even fewer pharynx cells ( $22.4 \pm 0.9$  ( $n = 24$ ) and  $22.1 \pm 1.4$  ( $n = 19$ ) than the  $\sim 30$  cells in the *med-1,2* or *tbx-35*; *ceh-51* backgrounds, comparable to *pop-1(RNAi)* alone ( $21.3 \pm 0.8$ ,  $n = 18$ ), and demonstrating a requirement for the Wnt/ $\beta$ -catenin asymmetry pathway in production of pharynx cells from the AB lineage (Kaletta et al., 1997; Lin et al., 1998). These results show that the MS-derived tissues made in *end-1,3*; *pop-1* embryos require the genes that normally specify MS. The detection of greater than 8 coelomocytes (as would be expected from  $2 \times$  MS cells in the embryo) further suggests that POP-1 plays a role in MS lineage asymmetries that give rise to coelomocyte precursors, a phenomenon that has been reported for postembryonically-specified coelomocytes (Amin et al., 2009).

#### E produces epidermal tissue as well as MS tissues in *end*; *pop-1* embryos

It is possible that in addition to MS-type cells, MS and/or E in *end*; *pop-1* mutant embryos could make cells that are normally derived from C. The Caudal-like regulator PAL-1, which specifies the C and D fates, is present in the early MS and E lineages, and is responsible for the C transformations that result when MS and E specification is compromised by mutation in the SKN-1/MED-1,2 pathway (Broitman-Maduro et al., 2006; Broitman-Maduro et al., 2009; Hunter and Kenyon, 1996; Maduro et al., 2005a). To evaluate this possibility, we



**Fig. 4.** Coelomocytes are made in *end-1,3*; *pop-1* mutant embryos. All embryos carry a *cup-4::GFP* coelomocyte-specific marker (Patton et al., 2005). (A) Wild-type embryo showing accumulation of *cup-4::GFP* expression in four coelomocytes (the top two are adjacent). (B) Normal coelomocytes in an *end-1(ok558)* *end-3(ok1448)* mutant. (C, D) Loss of coelomocytes in *pop-1(RNAi)* and *med-1(ok804)*; *med-2(cx9744)* embryos, in which a penetrant mis-specification of MS occurs (Broitman-Maduro et al., 2009; Lin et al., 1995; Maduro et al., 2001). (E, F) Supernumerary coelomocytes are made in *end-3(ok1448)*; *pop-1(RNAi)* embryos (average of  $6.1 \pm 0.2$  *cup-4::GFP*-expressing cells,  $n = 77$ ) and *end-1(ok558)* *end-3(ok1448)*; *pop-1(RNAi)* embryos (average of  $10.7 \pm 0.3$  cells,  $n = 77$ ). (G, H) Loss of coelomocytes in *med-1(ok804)*; *med-2(cx9744)*; *dpy-11(e224)* *end-1(ok558)* *end-3(ok1448)*; *pop-1(RNAi)* and *tbx-35(tm1789)*; *end-1(ok558)* *end-3(ok1448)* *ceh-51(tm2123)*; *pop-1(RNAi)* embryos. Faint yellow signal in some panels corresponds to gut granules.



**Fig. 5.** Expression of MS specification factors in *pop-1(RNAi)* and *end-1,3* mutant backgrounds. (A,B) Expression of a *tbx-35::GFP* reporter in wild-type and *pop-1(RNAi)* embryos. 100% ( $n=40$ ) of expressing embryos showed MS lineage-only expression in wild-type, while 12% ( $n=67$ ) of *tbx-35::GFP*-expressing *pop-1(RNAi)* embryos showed ectopic expression in the E lineage as shown; 75% of embryos overall had weak E lineage expression. (C–F) *In situ* hybridization with a *ceh-51* probe. (C) Wild-type staining pattern observed in 91% of embryos in the early MS lineage (MS<sup>2</sup> as shown here, or MS<sup>4</sup>;  $n=101$ ). (D) Ectopic expression of *ceh-51* in the early E lineage was observed in 86% ( $n=44$ ) of *pop-1(RNAi)* embryos (the remainder showed either normal expression or did not stain). Results in C and D were previously reported (Broitman-Maduro et al., 2009). (E) Weak ectopic expression of *ceh-51* in the E lineage (at E<sup>2</sup>, as shown here; ectopic expression was also observed at E<sup>4</sup>), as seen in 41% ( $n=209$ ) of progeny from *end-1(ok558) end-3(ok1448)* mothers carrying an *end-1,3 (+)* rescuing array. As this array is transmitted to ~50% of the progeny, ~80% of *end-1,3* mutant embryos showed activation of *ceh-51* in the E lineage. The remaining embryos showed wild-type expression (MS only). (F) Expression of *ceh-51* in MS and E was seen in 88% ( $n=45$ ) of *end-3(ok1448); pop-1(RNAi)* embryos. The remaining embryos were either unstained or appeared normal.

constructed an *end-1,3(ok1448)* strain carrying both a *cup-4::GFP* reporter, to mark coelomocytes, and an *nhr-25::YFP* reporter to mark epidermal cells (Baugh et al., 2005; Patton et al., 2005); the two reporters can be distinguished with appropriate filter sets (Miller et al., 1999). We used a laser microbeam to isolate MS or E and evaluated whether the resultant partial embryos produced epidermal cells, coelomocytes or both. MS blastomeres isolated from *end-1,3(ok1448); pop-1(RNAi)* embryos generated coelomocytes but not epidermal cells ( $n=4$ ), while isolated E blastomeres made coelomocytes all the time (6/6 embryos) and, simultaneously, epidermal cells part of the time (4/6 embryos). Therefore, in *end; pop-1* mutant embryos, E, but not MS, frequently adopts a mixed fate that includes production of tissues normally made by MS and C.

#### Early MS markers are expressed in E in *pop-1* and *end-1,3* mutant embryos

The production of pharynx cells from E in *end-1,3; pop-1(RNAi)* embryos suggests that POP-1 contributes to repression of MS fate in E. A role for POP-1 in repressing MS fate in E would explain why Wnt/ $\beta$ -catenin asymmetry mutants, which act upstream of POP-1, cause a transformation of E to MS, while loss of *end-1,3* results in an E to C transformation (Kaletta et al., 1997; Maduro et al., 2005a; Rocheleau et al., 1997; Rocheleau et al., 1999; Thorpe et al., 1997; Zhu et al., 1997). We previously failed to detect ectopic expression of the MS specification gene *tbx-35* in the E lineage in *pop-1* mutant embryos, either by *in situ* hybridization or a *tbx-35::GFP* reporter with 605 bp of putative *tbx-*

35 promoter (Broitman-Maduro et al., 2006). However, such ectopic expression was observed with a *tbx-35::GFP* reporter with 734 bp of promoter (Premnath Shetty and Rueyling Lin, personal communication; we reproduced this result with their reporter as shown in Figs. 5A, B). It was recently reported that *pop-1(RNAi)* embryos frequently showed expression of endogenous *ceh-51* and a *ceh-51::GFP* reporter in the early E lineage (Broitman-Maduro et al., 2009) (Figs. 5C, D). The ability of E to consistently produce MS tissues in *end-1,3; pop-1* mutant embryos suggested to us that loss of *end-1,3* may synergize with loss of *pop-1* to result in activation of MS genes. Indeed, we detected low levels of *ceh-51* transcripts in the E lineage in *end-1,3(ok1448)* mutants, consistent with a parallel role for END-1,3 in repressing MS fate (Fig. 5E). Furthermore, expression of *ceh-51* was strong in both the E and MS lineages in *end-3; pop-1(RNAi)* embryos, though no further enhancement of the expression seen in *pop-1(RNAi)* alone was noted (Fig. 5F). Taken together, these results confirm that the MS tissues made by E in *end; pop-1* embryos correlate with ectopic activation of MS specification in E, and they also provide evidence that POP-1 and END-1,3 contribute to the repression of early MS genes in the E lineage.

## Discussion

### Regulatory interactions in the *C. elegans* endomesoderm gene regulatory network

An updated gene network for *C. elegans* endomesoderm specification is shown in Fig. 6. Although this network focuses on EMS and its daughters, secondary mesoderm generated by ABA is included because it is induced by MS and involves downstream target genes that are shared with MS (Priess et al., 1987; Roy Chowdhuri et al., 2006; Smith and Mango, 2007). The network features early maternal factors that act combinatorially to direct blastomere-specific activation of transiently-expressed cell specification factors, which ultimately results in activation of stably-expressed tissue/organ identity factors in their descendants (Labouesse and Mango, 1999; Maduro, 2006; Maduro, 2008; Maduro and Rothman, 2002). The maternal inputs include SKN-1 (Bowerman et al., 1992; Maduro et al., 2001), POP-1 (Huang et al., 2007; Lin et al., 1995; Shetty et al., 2005), the Wnt/ $\beta$ -catenin asymmetry pathway that acts downstream of the P<sub>2</sub>-EMS interaction (Bei et al., 2002; Huang et al., 2007; Phillips et al., 2007; Rocheleau et al., 1997; Rocheleau et al., 1999; Thorpe et al., 1997), and the weak contribution by PAL-1 (Maduro et al., 2005b). Also included is the weak maternal contribution of MED-1,2 (Maduro et al., 2007), the evidence for which has been disputed by others (Captan et al., 2007). Within EMS, the only genes in the network are zygotic *med-1* and *med-2* (Maduro et al., 2001), and an unknown Delta-Serrate-Lag (DSL) gene that mediates the GLP-1/Notch-dependent cell-cell interaction that specifies pharynx from ABA (Mello et al., 1992; Priess et al., 1987). The MS/E zygotic factors as discussed above are activated combinatorially by the SKN-1 pathway and Wnt/ $\beta$ -catenin asymmetry pathway: These are *end-1* and *end-3*, which specify E, and *tbx-35* and *ceh-51*, which specify MS (Broitman-Maduro et al., 2009; Maduro et al., 2005a). As tissue/organogenesis factors, we have included the muscle regulatory network consisting of HND-1/Hand, HLH-1/MyoD, and UNC-120/SRF (Fukushige et al., 2006), the pharynx identity factor PHA-4/FoxA (Gaudet and Mango, 2002; Kaltenbach et al., 2005), genes that direct specification of pharynx cell subtypes (CEH-22/Nkx2.5 and HLH-6) (Okkema and Fire, 1994; Okkema et al., 1993; Raharjo and Gaudet, 2007; Vilimas et al., 2004), and factors required for specification of AB-derived pharynx (TBX-37/38) (Good et al., 2004) and AB-derived pharynx muscle (TBX-2) (Roy Chowdhuri et al., 2006; Smith and Mango, 2007). Based on genetic evidence that TBX-35 and CEH-51 define MS-derived muscle and pharynx, we have connected these regulators directly to the muscle network and *pha-4*, although evidence for direct interaction has not yet been obtained. Rather, the ability of PAL-1 to directly activate *hlh-1* in the C lineage strongly

## C. elegans Endomesoderm Specification




Fig. 6. Updated gene regulatory network for *C. elegans* endomesoderm generated with BioTapestry (Longabaugh et al., 2009) and modified in Adobe Photoshop. Some of the connections shown have been established at the protein–DNA level, while others have been inferred from genetic analysis. See Discussion for further details.

suggests that TBX-35 and/or CEH-51 may do the same in the MS lineage (Broitman-Maduro et al., 2009; Lei et al., 2009). As markers of terminal differentiation, the network includes as examples the pharynx muscle myosin gene *myo-2*, the body muscle myosin gene *myo-3*, the gut esterase gene *ges-1*, and the gut-expressed phosphatase gene *pho-1* (Fukushige et al., 2005; Kennedy et al., 1993; Okkema et al., 1993). The *elt-7* GATA factor is included, as it is activated at the same time as *elt-2* and may be involved in parallel functions with ELT-2 (Maduro and Rothman, 2002), and mutation of *elt-7* was reported to result in a decrease of intestinal expression of *pha-4* (Murray et al., 2008). The *elt-2* paralog *elt-4* appears to be non-functional and has not been included (Fukushige et al., 2003). As we have focused on early specification events, the model does not include many other regulators known to be involved in pharynx and intestine development; these have been described in recent reviews (Mango, 2007; McGhee, 2007).

From the studies presented here, we have included the apparent roles of END-1,3 in repression of *ceh-51* and the role of POP-1 in repression of *tbx-35*. As derepression of *tbx-35* was not complete in a *pop-1* mutant background, the model retains repression of *tbx-35* by an unknown Wnt-dependent repressor, accounting for persistent differences between the two EMS daughters in the absence of *pop-1* (discussed below). As the results presented here also do not require a positive input of POP-1 in specification of MS, it is not included. We note that this differs from the related nematode *C. briggsae*, in which an apparent positive role for POP-1, in parallel with SKN-1, is implied by RNAi knockdown experiments (also discussed below) (Lin et al., 2009).

#### A relatively mild phenotype of mutants lacking endoderm

We have reported the construction of a bona fide *end-1 end-3* double mutant strain and shown that it results in a complete failure of

endoderm specification, as predicted by prior experiments (Maduro et al., 2005a; Zhu et al., 1997). It might be expected that the complete mis-specification of a germ layer would result in profound changes to the remainder of embryonic development, but *end-1,3* mutants demonstrated a surprisingly mild phenotype, sometimes hatching into (inviable) larvae. By comparison, in *Drosophila*, loss of the endoderm (midgut) through mutation of the GATA factor *serpent* resulted in embryos that began gastrulation normally but eventually arrested, with midgut progenitors adopting ectodermal (hindgut and foregut) fates (Reuter, 1994). The mild phenotype of *C. elegans end-1,3* mutants explains why smaller deletions removing *end-1,3* alone (as opposed to large deletions removing hundreds of genes) were not isolated in screens for penetrant zygotic endoderm-defective mutants, if the design of the screens assumed that mis-specification of endoderm would result in a strict embryonic lethality (Maduro et al., 2005a; Zhu et al., 1997).

In *C. elegans end-1,3* mutant embryos, the transformed descendants of E are capable of an otherwise fairly normal morphogenesis of the embryo. In normal development, the E daughter cells are the first to ingress during gastrulation (Knight and Wood, 1998; Nance et al., 2005). The ability of most *end-1,3(-)* embryos to elongate suggests that there are mechanisms that can direct early gastrulation movements within the early E lineage independently of E specification, or that errors made during early E gastrulation are compensated by the embryo, or a combination of both mechanisms. Previous studies have used Wnt/ $\beta$ -catenin pathway mutants to perturb E specification and gastrulation (Lee et al., 2006; Rohrschneider and Nance, 2009), but these mutants may have effects outside of the E lineage. Hence, it may be that the chromosomal *end-1,3* double mutant will provide a new resource to further dissect the connection between gut specification and morphogenesis. It is also

possible that the double mutant will permit evaluation of contributions that the intestine makes to development, as *end-1,3* mutants had later phenotypes that are also seen in lysosomal trafficking mutants (Hermann et al., 2005).

*A hierarchy of specification pathways and reinforcement of fate choices*

Prior work on MS specification, and the analysis reported here, highlight the ability of blastomere specification pathways to exhibit phenotype prevalence. Normally, specification of MS and E is driven by activation of *tbx-35/ceh-51* in MS, and *end-1,3* in E (Broitman-Maduro et al., 2006; Broitman-Maduro et al., 2009; Maduro et al., 2005a). In *pop-1* mutant embryos, *end-1* and *end-3* become activated in MS, but *tbx-35* and *ceh-51* continue to be activated in MS as well (Broitman-Maduro et al., 2009; Maduro et al., 2007; Shetty et al., 2005). As well, maternal PAL-1 protein, which specifies the C lineage, is present in the early MS and E lineages (Hunter and Kenyon, 1996). Hence, in *pop-1* mutant embryos, the factors that specify E, MS and C all coexist within MS, and yet a high-penetrance MS to E transformation results in such embryos (Lin et al., 1995). Here we have shown that when *end-1* and *end-3* are removed in *pop-1* mutant embryos, MS can now be specified by TBX-35 and CEH-51. In mutants for *skn-1*, the *meds*, or *tbx-35/ceh-51*, MS adopts a C-like fate (Bowerman et al., 1992; Broitman-Maduro et al., 2006; Broitman-Maduro et al., 2009; Maduro et al., 2001). Taken together, this reveals a hierarchy of E>MS>C fates (Fig. 7). This is reminiscent of the posterior prevalence of Hox genes, in which the most posteriorly expressed Hox gene controls regional identity when multiple Hox genes are forcibly coexpressed, though it is almost certainly not the result of a similar mechanism (Capovilla and Botas, 1998; Yekta et al., 2008).


Unlike MS, which adopts an apparently strict MS, E or C fate in various mutant backgrounds (Bowerman et al., 1992; Broitman-Maduro et al., 2009; Lin et al., 1995), the E lineage can apparently adopt a mixed fate. We found that in an *end-1,3; pop-1* mutant background, E makes MS tissues (coelomocytes and pharynx) in all embryos, and epidermal cells, characteristic of C, some of the time (4/6 embryos). There are other examples of mixed E fates from prior studies. In *end-3* mutants, a small number of embryos showed apparent “half-guts” in which only one half of the intestine was present (Maduro et al., 2005a). In at least one lineage recording of an *end-3(zu247)* embryo, an E grand-daughter followed a lineage pattern that resembled an MS grand-daughter (Maduro et al., 2005a). The *end* genes are still sensitive to POP-1 repression in Ea (Maduro et al.,

2007), suggesting that it is possible for Ea and Ep to adopt different fates if *end* activity is partly compromised, but this mechanism does not explain how E can make both MS and C tissue types in a single embryo. Our analysis did not find evidence of production of C tissues from MS in *end-1,3; pop-1* embryos. While we detected similar levels of *ceh-51* expression in the MS and E lineages in *pop-1(RNAi)* embryos (Figs. 5C, D), this was not the case for *tbx-35*, in which a *tbx-35::GFP* reporter was activated only weakly (Figs. 5A, B) and which was not detected ectopically in E at all with a different reporter and in situ hybridization (Broitman-Maduro et al., 2006). The MS and E expression of *ceh-51::GFP* in *pop-1(RNAi)* embryos was found to be dependent on *tbx-35* (Broitman-Maduro et al., 2009), suggesting that some amount of TBX-35 is ectopically expressed in E in *pop-1(RNAi)* embryos, but it is at lower levels in E than in MS. The conclusion is that some differences between MS and E are still present in *pop-1*-depleted embryos.

These results nonetheless provide further evidence that Wnt-signaled POP-1 and END-1,3 also actively repress MS specification in E, perhaps as another Wnt-dependent mechanism to enforce an endodermal fate. Within MS, POP-1 is not modified by the Wnt/ $\beta$ -catenin asymmetry pathway, and *end-1,3* are repressed by POP-1, permitting the MEDs to activate *tbx-35* and the TBX-35 target *ceh-51* (Broitman-Maduro et al., 2006; Broitman-Maduro et al., 2009). We recently reported that while *ceh-51* activation is completely dependent on the MEDs for activation, *tbx-35* mutants still activate *ceh-51* at reduced levels, suggesting that another activator works in parallel with TBX-35 (Broitman-Maduro et al., 2009). Knockdown of *pop-1* by RNAi in a *tbx-35* mutant background resulted in abrogation of *ceh-51::GFP* expression, suggesting that this second factor is dependent on POP-1 (Broitman-Maduro et al., 2009). Hence, there is some evidence that unmodified POP-1 in MS contributes to MS fate, but this contribution is not at all evident from the phenotype data (as MS fate is restored to *end-1,3; pop-1* mutant embryos), and it is similarly not clear how POP-1 could activate expression of *ceh-51* in the MS daughters at equal levels, given that POP-1 asymmetry exists in MSa/p (Lin et al., 1998; Maduro et al., 2002).

*Comparisons between C. briggsae and C. elegans: network evolution*

In contrast to *C. elegans*, a positive contribution of POP-1 to MS fate was found in the related nematode *C. briggsae*. Although the embryonic lineages of *C. elegans* and *C. briggsae* are highly similar (Zhao et al., 2008), there are notable differences in the mechanisms of



**Fig. 7.** Summary of fate hierarchies revealed by EMS daughter cell fate transformations in various mutant backgrounds. Loss of *pop-1* results in an MS to E transformation (Lin et al., 1995); loss of Wnt/MAPK function causes an E to MS transformation (Rocheleau et al., 1997; Thorpe et al., 1997); for *skn-1* or *med-1,2* mutant embryos, MS adopts a C-like fate, while E appears to adopt either an E or C fate (Bowerman et al., 1992; Maduro et al., 2001); loss of *end-1,3* results in an E to C transformation (Maduro et al., 2005a; Zhu et al., 1997); loss of *tbx-35* and *ceh-51* results in a transformation of MS to C (Broitman-Maduro et al., 2009); and loss of *end-1,3* and *pop-1* together results in a restored partial MS lineage, and an apparent mixed fate from E that is a combination of MS and C fates (this work).

endomesoderm specification as determined by knockdown phenotypes. *C. elegans skn-1* mutants show a loss of MS and E tissues (Bowerman et al., 1992). In *C. briggsae*, knockdown of *Cb-skn-1* resulted in a more penetrant loss of endoderm, while GLP-1-independent pharynx was still made from MS (Lin et al., 2009). Knockdown of *Cb-pop-1* resulted in production of GLP-1-independent pharynx from both MS and E, and when *Cb-skn-1(RNAi)* and *Cb-pop-1(RNAi)* were performed simultaneously, both MS and E failed to make pharynx (Lin et al., 2009). Hence, there is a positive function for *Cb-POP-1* in specification of MS fate in parallel with *Cb-SKN-1*, and this mechanism is very different from *C. elegans*. Here we have confirmed that the primary contribution of *Ce-POP-1* to MS specification is repression of *Ce-end-1,3*, as loss of *Ce-pop-1* is compatible with MS specification if the *Ce-ends* are also mutated. While the mechanistic basis for these interspecific phenotype differences has yet to be elucidated, comparisons between the two species have already revealed flexibility in how the same genes can function differently in the same combinatorial specification events, and shown that for at least some apparently hardwired cell fate decisions, there is more than one way of accomplishing the same developmental endpoint. To this end, the weaker 'reinforcing' functions that have been identified in *C. elegans* may, in other species, be the primary mechanisms that determine blastomere fates.

## Acknowledgments

We thank Attila Stetak, Christian Frøkjær-Jensen, Erik Jørgensen and Andy Fire for plasmids, and Joel Rothman, Michael Krause, Premnath Shetty, Shuyi Huang, Rueyling Lin, Johnny Fares and Jim McGhee for transgenic strains. Some nematode strains used in this work were provided by the *Caenorhabditis* Genetics Center, which is funded by the NIH National Center for Research Resources (NCRR). The *ok558* and *ok1448* mutations were generated by the *C. elegans* Knockout Consortium. H.R. was an undergraduate trainee with the MARCU\* Program at UC Riverside. This work was supported by grants from the NSF (IBN#0416922 and IOS#0643325) and NIH (1R03HD054589-01) to M.M., and in part by NIH award T34GM062756 to UC Riverside.

## References

- Amin, N.M., Lim, S.E., Shi, H., Chan, T.L., Liu, J., 2009. A conserved Six-Eya cassette acts downstream of Wnt signaling to direct non-myogenic versus myogenic fates in the *C. elegans* postembryonic mesoderm. *Dev. Biol.* 331, 350–360.
- Baugh, L.R., Hill, A.A., Slonim, D.K., Brown, E.L., Hunter, C.P., 2003. Composition and dynamics of the *Caenorhabditis elegans* early embryonic transcriptome. *Development* 130, 889–900.
- Baugh, L.R., Hill, A.A., Claggett, J.M., Hill-Harfe, K., Wen, J.C., Slonim, D.K., Brown, E.L., Hunter, C.P., 2005. The homeodomain protein PAL-1 specifies a lineage-specific regulatory network in the *C. elegans* embryo. *Development* 132, 1843–1854.
- Bei, Y., Hogan, J., Berkowitz, L.A., Soto, M., Rocheleau, C.E., Pang, K.M., Collins, J., Mello, C.C., 2002. SRC-1 and Wnt signaling act together to specify endoderm and to control cleavage orientation in early *C. elegans* embryos. *Dev. Cell* 3, 113–125.
- Bowerman, B., Eaton, B.A., Priess, J.R., 1992. *skn-1*, a maternally expressed gene required to specify the fate of ventral blastomeres in the early *C. elegans* embryo. *Cell* 68, 1061–1075.
- Bowerman, B., Draper, B.W., Mello, C.C., Priess, J.R., 1993. The maternal gene *skn-1* encodes a protein that is distributed unequally in early *C. elegans* embryos. *Cell* 74, 443–452.
- Broitman-Maduro, G., Lin, K.T.H., Hung, W., Maduro, M., 2006. Specification of the *C. elegans* MS blastomere by the T-box factor TBX-35. *Development* 133, 3097–3106.
- Broitman-Maduro, G., Owrighi, M., Hung, W., Kuntz, S., Sternberg, P.W., Maduro, M., 2009. The NK-2 class homeodomain factor CEH-51 and the T-box factor TBX-35 have overlapping function in *C. elegans* mesoderm development. *Development* 136, 2735–2746.
- Capovilla, M., Botas, J., 1998. Functional dominance among Hox genes: repression dominates activation in the regulation of Dpp. *Development* 125, 4949–4957.
- Captan, V.V., Goszczynski, B., McGhee, J.D., 2007. Neither maternal nor zygotic *med-1/med-2* genes play a major role in specifying the *Caenorhabditis elegans* endoderm. *Genetics* 175, 969–974.
- Coroian, C., Broitman-Maduro, G., Maduro, M.F., 2005. Med-type GATA factors and the evolution of mesoderm specification in nematodes. *Dev. Biol.* 289, 444–455.
- Egan, C.R., Chung, M.A., Allen, F.L., Heschl, M.F., Van Buskirk, C.L., McGhee, J.D., 1995. A gut-to-pharynx/tail switch in embryonic expression of the *Caenorhabditis elegans ges-1* gene centers on two GATA sequences. *Dev. Biol.* 170, 397–419.
- Fay, D., 2006. Genetic mapping and manipulation: chapter 7—making compound mutants. *WormBook* 1–4.
- Fukushige, T., Hawkins, M.G., McGhee, J.D., 1998. The GATA-factor *elt-2* is essential for formation of the *Caenorhabditis elegans* intestine. *Dev. Biol.* 198, 286–302.
- Fukushige, T., Goszczynski, B., Tian, H., McGhee, J.D., 2003. The evolutionary duplication and probable demise of an endodermal GATA factor in *Caenorhabditis elegans*. *Genetics* 165, 575–588.
- Fukushige, T., Goszczynski, B., Yan, J., McGhee, J.D., 2005. Transcriptional control and patterning of the *pho-1* gene, an essential acid phosphatase expressed in the *C. elegans* intestine. *Dev. Biol.* 279, 446–461.
- Fukushige, T., Brodigan, T.M., Schriefer, L.A., Waterston, R.H., Krause, M., 2006. Defining the transcriptional redundancy of early bodywall muscle development in *C. elegans*: evidence for a unified theory of animal muscle development. *Genes Dev.* 20, 3395–3406.
- Gaudet, J., Mango, S.E., 2002. Regulation of organogenesis by the *Caenorhabditis elegans* FoxA protein PHA-4. *Science* 295, 821–825.
- Gillis, W.J., Bowerman, B., Schneider, S.Q., 2007. Ectoderm- and endomesoderm-specific GATA transcription factors in the marine annelid *Platynereis dumerilli*. *Evol. Dev.* 9, 39–50.
- Goldstein, B., 1992. Induction of gut in *Caenorhabditis elegans* embryos. *Nature* 357, 255–257.
- Good, K., Ciosk, R., Nance, J., Neves, A., Hill, R.J., Priess, J.R., 2004. The T-box transcription factors TBX-37 and TBX-38 link GLP-1/Notch signaling to mesoderm induction in *C. elegans* embryos. *Development* 131, 1967–1978.
- Goszczynski, B., McGhee, J.D., 2005. Re-evaluation of the role of the *med-1* and *med-2* genes in specifying the *C. elegans* endoderm. *Genetics* 171, 545–555.
- Hermann, G.J., Schroeder, L.K., Hieb, C.A., Kershner, A.M., Rabbitts, B.M., Fonarev, P., Grant, B.D., Priess, J.R., 2005. Genetic analysis of lysosomal trafficking in *Caenorhabditis elegans*. *Mol. Biol. Cell* 16, 3273–3288.
- Horner, M.A., Quintin, S., Domeier, M.E., Kimble, J., Labouesse, M., Mango, S.E., 1998. *pha-4*, an HNF-3 homolog, specifies pharyngeal organ identity in *Caenorhabditis elegans*. *Genes Dev.* 12, 1947–1952.
- Huang, S., Shetty, P., Robertson, S.M., Lin, R., 2007. Binary cell fate specification during *C. elegans* embryogenesis driven by reiterated reciprocal asymmetry of TCF POP-1 and its coactivator beta-catenin SYS-1. *Development* 134, 2685–2695.
- Hunter, C.P., Kenyon, C., 1996. Spatial and temporal controls target *pal-1* blastomere-specific activity to a single blastomere lineage in *C. elegans* embryos. *Cell* 87, 217–226.
- Kalb, J.M., Lau, K.K., Goszczynski, B., Fukushige, T., Moons, D., Okkema, P.G., McGhee, J.D., 1998. *pha-4* is *Ce-fkh-1*, a fork head/HNF-3alpha,beta,gamma homolog that functions in organogenesis of the *C. elegans* pharynx. *Development* 125, 2171–2180.
- Kaletta, T., Schnabel, H., Schnabel, R., 1997. Binary specification of the embryonic lineage in *Caenorhabditis elegans*. *Nature* 390, 294–298.
- Kaltenbach, L.S., Updike, D.L., Mango, S.E., 2005. Contribution of the amino and carboxyl termini for PHA-4/FoxA function in *Caenorhabditis elegans*. *Dev. Dyn.* 234, 346–354.
- Kennedy, B.P., Aamodt, E.J., Allen, F.L., Chung, M.A., Heschl, M.F., McGhee, J.D., 1993. The gut esterase gene (*ges-1*) from the nematodes *Caenorhabditis elegans* and *Caenorhabditis briggsae*. *J. Mol. Biol.* 229, 890–908.
- Knight, J.K., Wood, W.B., 1998. Gastrulation initiation in *Caenorhabditis elegans* requires the function of *gad-1*, which encodes a protein with WD repeats. *Dev. Biol.* 198, 253–265.
- Labouesse, M., Mango, S.E., 1999. Patterning the *C. elegans* embryo: moving beyond the cell lineage. *Trends Genet.* 15, 307–313.
- Laufer, J.S., Bazzicalupo, P., Wood, W.B., 1980. Segregation of developmental potential in early embryos of *Caenorhabditis elegans*. *Cell* 19, 569–577.
- Lee, J.Y., Marston, D.J., Walston, T., Hardin, J., Halberstadt, A., Goldstein, B., 2006. Wnt/ Frizzled signaling controls *C. elegans* gastrulation by activating actomyosin contractility. *Curr. Biol.* 16, 1986–1997.
- Lei, H., Liu, J., Fukushige, T., Fire, A., Krause, M., 2009. Caudal-like PAL-1 directly activates the bodywall muscle module regulator *hlh-1* in *C. elegans* to initiate the embryonic muscle gene regulatory network. *Development* 136, 1241–1249.
- Lin, R., 2003. A gain-of-function mutation in *oma-1*, a *C. elegans* gene required for oocyte maturation, results in delayed degradation of maternal proteins and embryonic lethality. *Dev. Biol.* 258, 226–239.
- Lin, R., Thompson, S., Priess, J.R., 1995. *pop-1* encodes an HMG box protein required for the specification of a mesoderm precursor in early *C. elegans* embryos. *Cell* 83, 599–609.
- Lin, R., Hill, R.J., Priess, J.R., 1998. POP-1 and anterior-posterior fate decisions in *C. elegans* embryos. *Cell* 92, 229–239.
- Lin, K.T., Broitman-Maduro, G., Hung, W.W., Cervantes, S., Maduro, M.F., 2009. Knockdown of SKN-1 and the Wnt effector TCF/POP-1 reveals differences in endomesoderm specification in *C. briggsae* as compared with *C. elegans*. *Dev. Biol.* 325, 296–306.
- Longabaugh, W.J., Davidson, E.H., Bolouri, H., 2009. Visualization, documentation, analysis, and communication of large-scale gene regulatory networks. *Biochim. Biophys. Acta* 1789, 363–374.
- Lowry, J.A., Athley, W.R., 2000. Molecular evolution of the GATA family of transcription factors: conservation within the DNA-binding domain. *J. Mol. Evol.* 50, 103–115.
- Lowry, J.A., Gamsjaeger, R., Thong, S.Y., Hung, W., Kwan, A.H., Broitman-Maduro, G., Matthews, J.M., Maduro, M., Mackay, J.P., 2009. Structural analysis of MED-1 reveals unexpected diversity in the mechanism of DNA recognition by GATA-type zinc finger domains. *J. Biol. Chem.* 284, 5827–5835.
- Maduro, M.F., 2006. Endomesoderm specification in *Caenorhabditis elegans* and other nematodes. *BioEssays* 28, 1010–1022.

- Maduro, M.F., 2008. Structure and evolution of the *C. elegans* embryonic endomesoderm network. *Biochim. Biophys. Acta* 1789, 250–260.
- Maduro, M.F., Rothman, J.H., 2002. Making worm guts: the gene regulatory network of the *Caenorhabditis elegans* endoderm. *Dev. Biol.* 246, 68–85.
- Maduro, M.F., Meneghini, M.D., Bowerman, B., Broitman-Maduro, G., Rothman, J.H., 2001. Restriction of mesoderm to a single blastomere by the combined action of SKN-1 and a GSK-3beta homolog is mediated by MED-1 and -2 in *C. elegans*. *Mol. Cell* 7, 475–485.
- Maduro, M.F., Lin, R., Rothman, J.H., 2002. Dynamics of a developmental switch: recursive intracellular and intranuclear redistribution of *Caenorhabditis elegans* POP-1 parallels Wnt-inhibited transcriptional repression. *Dev. Biol.* 248, 128–142.
- Maduro, M., Hill, R.J., Heid, P.J., Newman-Smith, E.D., Zhu, J., Priess, J., Rothman, J., 2005a. Genetic redundancy in endoderm specification within the genus *Caenorhabditis*. *Dev. Biol.* 284, 509–522.
- Maduro, M.F., Kasmir, J.J., Zhu, J., Rothman, J.H., 2005b. The Wnt effector POP-1 and the PAL-1/Caudal homeoprotein collaborate with SKN-1 to activate *C. elegans* endoderm development. *Dev. Biol.* 285, 510–523.
- Maduro, M.F., Broitman-Maduro, G., Mengarelli, I., Rothman, J.H., 2007. Maternal deployment of the embryonic SKN-1->MED-1,2 cell specification pathway in *C. elegans*. *Dev. Biol.* 301, 590–601.
- Mango, S.E., 2007. The *C. elegans* pharynx: a model for organogenesis. *WormBook* 1–26.
- McGhee, J.D., 2007. The *C. elegans* intestine. *WormBook* 1–36.
- McGhee, J.D., Sleumer, M.C., Bilenky, M., Wong, K., McKay, S.J., Goszczynski, B., Tian, H., Krich, N.D., Khattra, J., Holt, R.A., Baillie, D.L., Kohara, Y., Marra, M.A., Jones, S.J., Moerman, D.G., Robertson, A.G., 2007. The ELT-2 GATA-factor and the global regulation of transcription in the *C. elegans* intestine. *Dev. Biol.* 302, 627–645.
- McGhee, J.D., Fukushige, T., Krause, M.W., Minnema, S.E., Goszczynski, B., Gaudet, J., Kohara, Y., Bossinger, O., Zhao, Y., Khattra, J., Hirst, M., Jones, S.J., Marra, M.A., Ruzanov, P., Warner, A., Zapf, R., Moerman, D.G., Kalb, J.M., 2009. ELT-2 is the predominant transcription factor controlling differentiation and function of the *C. elegans* intestine, from embryo to adult. *Dev. Biol.* 327, 551–565.
- Mello, C.C., Draper, B.W., Krause, M., Weintraub, H., Priess, J.R., 1992. The pie-1 and mex-1 genes and maternal control of blastomere identity in early *C. elegans* embryos. *Cell* 70, 163–176.
- Mello, C.C., Draper, B.W., Priess, J.R., 1994. The maternal genes apx-1 and glp-1 and establishment of dorsal-ventral polarity in the early *C. elegans* embryo. *Cell* 77, 95–106.
- Meneghini, M.D., Ishitani, T., Carter, J.C., Hisamoto, N., Ninomiya-Tsuji, J., Thorpe, C.J., Hamill, D.R., Matsumoto, K., Bowerman, B., 1999. MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in *Caenorhabditis elegans*. *Nature* 399, 793–797.
- Miller, D.M., III, Desai, N.S., Hardin, D.C., Piston, D.W., Patterson, G.H., Fleenor, J., Xu, S., Fire, A., 1999. Two-color GFP expression system for *C. elegans*. *Biotechniques* 26, 914–8, 920–1.
- Mizumoto, K., Sawa, H., 2007. Two betas or not two betas: regulation of asymmetric division by beta-catenin. *Trends Cell Biol.* 17, 465–473.
- Murray, J.I., Bao, Z., Boyle, T.J., Boeck, M.E., Mericle, B.L., Nicholas, T.J., Zhao, Z., Sandel, M.J., Waterston, R.H., 2008. Automated analysis of embryonic gene expression with cellular resolution in *C. elegans*. *Nat. Methods* 5, 703–709.
- Nance, J., Lee, J.Y., Goldstein, B., 2005. Gastrulation in *C. elegans*. *WormBook* 1–13.
- Okkema, P.G., Fire, A., 1994. The *Caenorhabditis elegans* NK-2 class homeoprotein CEH-22 is involved in combinatorial activation of gene expression in pharyngeal muscle. *Development* 120, 2175–2186.
- Okkema, P.G., Harrison, S.W., Plunger, V., Aryana, A., Fire, A., 1993. Sequence requirements for myosin gene expression and regulation in *Caenorhabditis elegans*. *Genetics* 135, 385–404.
- Page, B.D., Diede, S.J., Tenlen, J.R., Ferguson, E.L., 2007. EEL-1, a Hect E3 ubiquitin ligase, controls asymmetry and persistence of the SKN-1 transcription factor in the early *C. elegans* embryo. *Development* 134, 2303–2314.
- Patton, A., Knuth, S., Schaheen, B., Dang, H., Greenwald, I., Fares, H., 2005. Endocytosis function of a ligand-gated ion channel homolog in *Caenorhabditis elegans*. *Curr. Biol.* 15, 1045–1050.
- Pauli, F., Liu, Y., Kim, Y.A., Chen, P.J., Kim, S.K., 2006. Chromosomal clustering and GATA transcriptional regulation of intestine-expressed genes in *C. elegans*. *Development* 133, 287–295.
- Phillips, B.T., Kidd 3rd, A.R., King, R., Hardin, J., Kimble, J., 2007. Reciprocal asymmetry of SYS-1/beta-catenin and POP-1/TCF controls asymmetric divisions in *Caenorhabditis elegans*. *Proc. Natl. Acad. Sci. U. S. A.* 104, 3231–3236.
- Priess, J.R., Schnabel, H., Schnabel, R., 1987. The glp-1 locus and cellular interactions in early *C. elegans* embryos. *Cell* 51, 601–611.
- Raharjo, I., Gaudet, J., 2007. Gland-specific expression of *C. elegans* hih-6 requires the combinatorial action of three distinct promoter elements. *Dev. Biol.* 302, 295–308.
- Reuter, R., 1994. The gene serpent has homeotic properties and specifies endoderm versus ectoderm within the *Drosophila* gut. *Development* 120, 1123–1135.
- Rocheleau, C.E., Downs, W.D., Lin, R., Wittmann, C., Bei, Y., Cha, Y.H., Ali, M., Priess, J.R., Mello, C.C., 1997. Wnt signaling and an APC-related gene specify endoderm in early *C. elegans* embryos. *Cell* 90, 707–716.
- Rocheleau, C.E., Yasuda, J., Shin, T.H., Lin, R., Sawa, H., Okano, H., Priess, J.R., Davis, R.J., Mello, C.C., 1999. WRM-1 activates the LIT-1 protein kinase to transduce anterior/posterior polarity signals in *C. elegans*. *Cell* 97, 717–726.
- Rohrschneider, M.R., Nance, J., 2009. Polarity and cell fate specification in the control of *Caenorhabditis elegans* gastrulation. *Dev. Dyn.* 238, 789–796.
- Roy, P.J., Stuart, J.M., Lund, J., Kim, S.K., 2002. Chromosomal clustering of muscle-expressed genes in *Caenorhabditis elegans*. *Nature* 418, 975–979.
- Roy Chowdhuri, S., Crum, T., Woollard, A., Aslam, S., Okkema, P.G., 2006. The T-box factor TBX-2 and the SUMO conjugating enzyme UBC-9 are required for ABA-derived pharyngeal muscle in *C. elegans*. *Dev. Biol.* 295, 664–677.
- Schroeder, D.F., McGhee, J.D., 1998. Anterior-posterior patterning within the *Caenorhabditis elegans* endoderm. *Development* 125, 4877–4887.
- Shetty, P., Lo, M.C., Robertson, S.M., Lin, R., 2005. *C. elegans* TCF protein, POP-1, converts from repressor to activator as a result of Wnt-induced lowering of nuclear levels. *Dev. Biol.* 285, 584–592.
- Shin, T.H., Yasuda, J., Rocheleau, C.E., Lin, R., Soto, M., Bei, Y., Davis, R.J., Mello, C.C., 1999. MOM-4, a MAP kinase kinase kinase-related protein, activates WRM-1/LIT-1 kinase to transduce anterior/posterior polarity signals in *C. elegans*. *Mol. Cell.* 4, 275–280.
- Shirayama, M., Soto, M.C., Ishidate, T., Kim, S., Nakamura, K., Bei, Y., van den Heuvel, S., Mello, C.C., 2006. The conserved kinases CDK-1, GSK-3, KIN-19, and MBK-2 promote OMA-1 destruction to regulate the oocyte-to-embryo transition in *C. elegans*. *Curr. Biol.* 16, 47–55.
- Smith, P.A., Mango, S.E., 2007. Role of T-box gene *tbx-2* for anterior foregut muscle development in *C. elegans*. *Dev. Biol.* 302, 25–39.
- Sulston, J.E., Schierenberg, E., White, J.G., Thomson, J.N., 1983. The embryonic cell lineage of the nematode *Caenorhabditis elegans*. *Dev. Biol.* 100, 64–119.
- Thorpe, C.J., Schlesinger, A., Carter, J.C., Bowerman, B., 1997. Wnt signaling polarizes an early *C. elegans* blastomere to distinguish endoderm from mesoderm. *Cell* 90, 695–705.
- Vilimas, T., Abraham, A., Okkema, P.G., 2004. An early pharyngeal muscle enhancer from the *Caenorhabditis elegans* *ceh-22* gene is targeted by the Forkhead factor PHA-4. *Dev. Biol.* 266, 388–398.
- Yekta, S., Tabin, C.J., Bartel, D.P., 2008. MicroRNAs in the Hox network: an apparent link to posterior prevalence. *Nat. Rev. Genet.* 9, 789–796.
- Yochem, J., Gu, T., Han, M., 1998. A new marker for mosaic analysis in *Caenorhabditis elegans* indicates a fusion between *hyp6* and *hyp7*, two major components of the hypodermis. *Genetics* 149, 1323–1334.
- Zhao, Z., Boyle, T.J., Bao, Z., Murray, J.I., Mericle, B., Waterston, R.H., 2008. Comparative analysis of embryonic cell lineage between *Caenorhabditis briggsae* and *Caenorhabditis elegans*. *Dev. Biol.* 314, 93–99.
- Zhu, J., Hill, R.J., Heid, P.J., Fukuyama, M., Sugimoto, A., Priess, J.R., Rothman, J.H., 1997. end-1 encodes an apparent GATA factor that specifies the endoderm precursor in *Caenorhabditis elegans* embryos. *Genes Dev.* 11, 2883–2896.